<DOC>
	<DOCNO>NCT00111995</DOCNO>
	<brief_summary>This study design evaluate hemoglobin response Aranesp® ( darbepoetin alfa ) black subject ( African-Americans ) chronic renal failure ( CRF ) receive hemodialysis examine safety profile .</brief_summary>
	<brief_title>Evaluating Aranesp® Treatment Anemia African-American Subjects With Chronic Renal Failure ( CRF ) Receiving Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis CRF 3 time weekly prescribe hemodialysis treatment least 8 week sign informed consent No plan change dialysis modality schedule Black ( indicate Chronic Medical Evidence Disease Report , CMMS Form 2728 ) Hemoglobin 9.5 12.5 g/dL 2 consecutive occasion screen period ( 1 week + 2 day apart ) baseline hemoglobin level 9.5 12.5 g/dL ( define mean measurement take screen baseline period ) Transferrin saturation great equal 20 % less equal 50 % Stable rHuEPO therapy give 3 time per week intravenous ( IV ) route administration 6 week randomization ( stable define less equal 25 % change prescribe dose 6 week , route administration , 1 miss withhold dose two 3week period randomization ) Scheduled livingrelated living nonrelated donor transplant rHuEPO dose great 40,000 unit weekly Uncontrolled hypertension ( postdialysis diastolic blood pressure great 105 mmHg and/or systolic blood pressure great 180 mmHg 1 occasion note collected blood pressure measurement screening/baseline period ) Congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) Major surgery ( exclude vascular access surgery ) within 8 week sign informed consent screening/baseline Clinical evidence active inflammatory disease require cyclophosphamide , azathioprine , prednisone immunosuppressive therapy within 8 week sign informed consent screening/baseline Currently ( sign inform consent ) receive antibiotic systemic infection screening/baseline Known positivity HIV antibody hepatitis B surface antigen Grand mal seizure within last year Clinical evidence current malignancy ( nonmelanomatous skin malignancy ) , and/or receive chemotherapy , and/or radiation therapy malignancy within 8 week sign informed consent screening/baseline Active systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematological malignancy , myeloma , hemolytic anemia ) within 8 week sign informed consent screening/baseline Clinical evidence severe hyperparathyroidism ( parathyroid hormone [ PTH ] level great 1500 pg/mL biopsyproven bone marrow fibrosis ) last measurement ALT AST great 2x upper limit normal range Red blood cell transfusion within 8 week sign informed consent screening/baseline Known hypersensitivity human serum albumin ( HSA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Chronic Renal Failure ( CRF )</keyword>
	<keyword>Anemia</keyword>
</DOC>